
On Monday, Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) reported data from patients in Cohort nine of the dose escalation portion of the RESOLVE trial in Eosinophilic Esophagitis (EoE) patients, the first time patients received an 8mg dose per injection.
Select Data: